GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Amexdrug AXRX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$3.4m

FY2014FY2024

Net income

$11,436

FY2014FY2024

Free cash flow

—

FY2014FY2024

Shareholders' equity

$1.8m

FY2014FY2024

Income statement

Fiscal years

FY2024FY2023FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Revenue$3.4m$3.9m$4.8m$6.4m$7.7m$10.5m$10.4m$9.3m$8.9m$8.6m
Gross profit$1.1m$1.0m$995,158$1.6m$1.5m$1.7m$2.0m$1.6m$1.1m$1.1m
Research and development———$18,104$75,147$92,283$69,200$37,500——
Operating income$120,117$117,128$136,450$314,720$280,070$249,120$214,620$145,630$168,430$154,033
Net income$11,436$35,833$74,192$195,991$216,891$201,399$111,364$73,759$100,314$76,455
Diluted earnings per share0.000.000.000.000.000.000.000.000.000.00

Balance sheet

At each fiscal year end

FY2024FY2023FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Total assets$2.5m$2.5m$2.9m$3.7m$2.5m$2.7m$2.3m$2.3m$1.8m$1.4m
Cash and short-term investments$1.7m$1.3m$1.6m$2.0m$458,835$288,065$245,025$222,178$241,476—
Total liabilities$720,817$706,738$1.2m$2.2m$1.2m$1.7m$1.5m$1.6m$1.2m$865,932
Debt$463,318$491,404$814,725$2.0m$890,800$359,686$799,662$808,023$703,023$548,045
Shareholders' equity$1.8m$1.8m$1.6m$1.5m$1.3m$1.0m$806,692$697,600$624,770$525,550
Shares outstanding169m169m169m169m169m173m169m166m169m169m

Cash flow

Fiscal years

FY2024FY2023FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014
Cash from operations——————$27,486−$121,201$17,636$142,547
Capital spending————————−$800−$1,397
Free cash flow——————$27,486−$121,201$16,836$141,150

Latest quarters

By quarter end

Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023
Revenue$754,641$767,365$804,532$801,550$836,375$956,172$955,078$949,612
Gross profit$298,604$453,160$49,511$312,449$314,356$398,297$292,317$226,731
Operating income$65,098$32,260−$3,503$26,985$43,900$52,730$46,370−$48,050
Net income$31,343$15,562−$37,060$9,702$15,322$23,472$30,237−$67,466
Diluted earnings per share0.000.00-0.000.000.000.000.00-0.00
Total assets$2.4m$2.4m$2.5m$2.2m$2.4m$2.5m$2.5m$2.2m
Cash and short-term investments$1.7m$1.5m$1.7m$1.5m$1.6m$1.4m$1.3m$1.2m
Debt——————$1,050$1,050
Shareholders' equity$1.8m$1.8m$1.8m$1.8m$1.8m$1.8m$1.8m$1.7m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-18.9%-20.2%-9.4%
Operating income-27.5%-13.6%-4.8%
Net income-61.2%-43.7%-17.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin28.9%25.2%21.5%17.6%
Operating margin3.2%3.7%3.3%2.5%
Net margin0.6%1.7%2.0%1.4%

Valuation history

At each fiscal year end

FY2024FY2023FY2021FY2020FY2018
Price to earnings29.69.5137.00.70.0
Price to sales0.10.12.10.0—

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-90%82%-98%9%10688%15666%-48%531%10531%1037%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 20-for-1 split · 3 Dec 2012

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.